Belimumab After Rituximab in Resistant Primary Juvenile SS

The goal of this clinical trial is to explore the effectiveness of sequential use of rituximab and belimumab in the treatment of resistant primary juvenile Sjogren's syndrome. Does sequential use of rituximab and belimumab reduce the activity of SS in resistant patients Researchers will compare the disease activity before and after the treatment of sequential use of rituximab and belimumab to see if the therapy works to treat SS. Participants will: Recieve Rituximab each week for 2-4 times until B%\<0.5% or B#\<20×10\^6/L Recieve Belimumab 4 weeks after the last use of Rituximab, and then

Trial Details

NCT ID
NCT06410833
Phase
PHASE4
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Rituximab
  • Belimumab
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Age 5-18 years old.
  • Meets SS diagnostic AECG criteria or Japan criteria.
  • classification for "resistant patients": Application of two or more immunosuppressants or prednisone +immunosuppressive therapy for more than 3 mon…
  • Agree to receive the treatment of rituximab combined with belimumab

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →